Verastem (VSTM) Gross Margin (2018 - 2026)

Verastem (VSTM) posted quarterly Gross Margin of 85.15% for Q1 2026, little changed quarter-over-quarter from 85.1% in Q4 2025.

Analysis

Verastem (VSTM) Gross Margin (2018 - 2026) Analysis & Trends

Verastem's Gross Margin history runs 5 years deep, the most recent figure standing at 85.15% for Q1 2026.

In Q1 2026, Gross Margin changed N/A year-over-year to 85.15%; the TTM figure through Mar 2026 stood at 85.13% (changed N/A YoY), while the FY2025 annual figure was 85.12%, changed N/A from the prior year.
Gross Margin for Q1 2026 stood at 85.15%, roughly flat from 85.1% in the prior quarter.
The five-year high for Gross Margin was 85.15% in Q1 2026, with the low at 85.1% in Q4 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	85.33%
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	91.59%
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	90.43%
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	35.86%
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	89.76%
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	76.90%
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	84.20%
10	Verastem	814.94 Mn	678.59 Mn	36.32 Mn	90.61%

Historic Data

Download Data